Scarica l'app Stockscreener
29.03
3.49%
-1.05
Dopo l'orario di chiusura:
29.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$30.08
Aprire:
$30
Volume 24 ore:
736.43K
Relative Volume:
1.04
Capitalizzazione di mercato:
$1.81B
Reddito:
$32.08M
Utile/perdita netta:
$-169.77M
Rapporto P/E:
-10.22
EPS:
-2.8418
Flusso di cassa netto:
$-147.70M
1 W Prestazione:
-11.06%
1M Prestazione:
-22.11%
6M Prestazione:
+0.38%
1 anno Prestazione:
+197.44%
Intervallo 1D:
$28.61
$30.55
Intervallo di 1 settimana:
$28.61
$33.02
Portata 52W:
$9.09
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
29.03 | 1.87B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-05 | Iniziato | Guggenheim | Buy |
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 - BioSpace
Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake - Stock Titan
Technical Reactions to STOK Trends in Macro Strategies - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK) - Stock Titan
Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK) - Stock Titan
TD Bank (NASDAQ: STOK) reports 3.18M shares, 5.4% stake - Stock Titan
RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK) - Stock Titan
Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK) - Stock Titan
STOK Should I Buy - Intellectia AI
HC Wainwright Analysts Boost Earnings Estimates for STOK - MarketBeat
Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance - MSN
Stoke Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-05-11 - Seeking Alpha
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at BTIG Research - MarketBeat
STOK Reiterates by BTIG -- Price Target Maintained at $39.00 - GuruFocus
Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60 - Moomoo
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60 - Moomoo
Stoke Therapeutics Q1 Earnings Call Highlights - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Stoke Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
Transcript : Stoke Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Stoke Therapeutics Q1 2026 slides show zorevunersen Phase 3 progress By Investing.com - Investing.com Canada
Earnings call transcript: Stoke Therapeutics Q1 2026 results show mixed performance By Investing.com - Investing.com South Africa
Earnings call transcript: Stoke Therapeutics Q1 2026 results show mixed performance - Investing.com Nigeria
Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion - ChartMill
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Why Stoke Therapeutics Stock Is Sliding Hard Today - TipRanks
STOKE THERAPEUTICS Q1 EPS USD -0.79 - Moomoo
Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q1 Revenue $6.2M, vs. FactSet Est of $6.5M - marketscreener.com
Stoke Therapeutics (Nasdaq: STOK) Q1 2026 loss, zorevunersen data and cash runway to 2028 - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) swings to Q1 2026 loss as Biogen upfront revenue rolls off - Stock Titan
Stoke Therapeutics faces earnings test after revenue miss By Investing.com - Investing.com Nigeria
Stoke Therapeutics faces earnings test after revenue miss - Investing.com UK
Trading the Move, Not the Narrative: (STOK) Edition - Stock Traders Daily
Privium Fund Management B.V. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 2,243 shares in open-market trade - Stock Titan
Hussman Strategic Advisors Inc. Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Baruch S. Ticho sells STOK shares under 10b5-1 (STOK) - Stock Titan
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome (STOK) - Seeking Alpha
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates - BioSpace
Epilepsy Pipeline Grows as 75+ Pharma Companies Advance 90+ - openPR.com
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):